Drug Trial Radar · NCT04280718
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
229
Actual
Start
Sep 18, 2020
Primary completion
Apr 30, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- argenxargenx (ARGX)
- Sponsor type
- Industry
- First posted
- Feb 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is the open-label extension study of phase II ARGX-113-1802 to evaluate the long-term safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP. Patients already stabilized on efgartigimod PH20 SC will also have the opportunity to participate in a sub study to explore less frequent dosing of efgartigimod PH20 SC.
Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Interventions
Efgartigimod PH20 SCBiological
Subcutaneous administration of efgartigimod
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events and serious adverse eventsTime frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study
Locations
147 sites in 24 countries. Site status is shown where the registry gives one.
Investigator site 0010065
Birmingham, Alabama
Investigator site 0010013
Phoenix, Arizona
Investigator site 0010055
Scottsdale, Arizona
Investigator site 0010032
Carlsbad, California
Investigator site 10190
Pomona, California
Investigator site 0010160
Rancho Mirage, California
Investigator site 0010071
San Francisco, California
Investigator site 0010057
Centennial, Colorado
Investigator site 0010072
Boca Raton, Florida
Investigator site 0010144
Coral Springs, Florida
Investigator site 0010023
Jacksonville, Florida
Investigator site 0010068
Maitland, Florida
Investigator site 0010059
Miami, Florida
Investigator site 0010006
Tampa, Florida
Investigator site 0010011
Iowa City, Iowa
Investigator site 0010015
Fairway, Kansas
Investigator site 10147
Lexington, Kentucky
Investigator site 10168
New York, New York
Investigator site 0010003
Chapel Hill, North Carolina
Investigator site 0010064
Columbus, Ohio
Investigator site 0010007
Philadelphia, Pennsylvania
Investigator site 0010047
Philadelphia, Pennsylvania
Investigator Site 0010066
Austin, Texas
Investigator site 0010009
San Antonio, Texas
Investigator site 0010061
Richmond, Virginia
Investigator site 0430007
Innsbruck, Austria
Investigator site 0430008
Linz, Austria
Investigator site 0430005
Vienna, Austria
Investigator site 0320016
Edegem, Belgium
Investigator site 0320009
Leuven, Belgium
Investigator site 320024
Liège, Belgium
Investigator site 320022
Woluwe-Saint-Lambert, Belgium
Investigator site 3590007
Pleven, Bulgaria
Investigator site 3590005
Sofia, Bulgaria
Investigator site 3590008
Sofia, Bulgaria
Investigator site 3590006
Sofia, Bulgaria
Investigator site 0860033
Beijing, China
Investigator site 860041
Changsha, China
Investigator site 0860036
Chengdu, China
Investigator site 860049
Chifeng, China
Showing 40 of 147 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.